A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients.
about
Posttransplant lymphoproliferative disease after pediatric solid organ transplantationPediatric heart transplantation-indications and outcomes in the current era.Rituximab is Indispensable for Pediatric Heart Transplant Recipients Developing Post Transplant Lymphoproliferative Disorders.Ten yr of pediatric heart transplantation: a report from the Pediatric Heart Transplant Study.Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients.Posttransplant Lymphoproliferative Disorder: Otolaryngological Manifestations and Management.Incidental EBV-positivity in paediatric post-transplant specimens demonstrates the need for stringent criteria for diagnosing post-transplant lymphoproliferative disorders.Post-transplant lymphoproliferative disease is associated with early sternotomy and left ventricular hypoplasia during infancy: a population-based retrospective review.Severe post-transplant lymphoproliferative disorder after living donor liver transplantation.Influence of Posttransplant Lymphoproliferative Disorder on Survival in Children After Heart Transplantation.Risk factors for specific causes of death following pediatric heart transplant: An analysis of the registry of the International Society of Heart and Lung Transplantation.Successful treatment of systemic and central nervous system post-transplant lymphoproliferative disorder without the use of high-dose methotrexate or radiation.In vivo intratumoral Epstein-Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications.Airway plaque presenting after alteration of immunosuppression in a pediatric patient remote from heart transplantation.Neonatal heart transplantation.The pathological implications of heart transplantation: experience with 50 cases in a single center.Construction and Characterization of a Humanized Anti-Epstein-Barr Virus gp350 Antibody with Neutralizing Activity in Cell Culture.Posttransplant Lymphoproliferative Disorder after Cardiac Transplantation in Children: Life Threatening Complications Associated with Chemotherapy Combined with Rituximab
P2860
Q26866013-0C0EC377-D131-4E90-9F6B-FB1D5BC22DD3Q34048053-13C8DE85-5CC9-4AE2-BAB4-2C2D2B9D4C45Q37579288-2FDA70F7-C754-47CC-905E-3B5E570ABDABQ38084741-610E317A-2606-4992-8AA7-ED321EA355CFQ38117179-590B8B2F-2AA7-4119-9D03-1D9F9A7D26B4Q38680172-35E575BC-57FB-4BAF-B0A7-484E4D622610Q39182562-390D5FB2-7B3C-4E8C-86CA-637E765708DAQ40093152-BB1DD493-14D0-4A65-8261-8B0DE3D506B3Q40209732-9E1F33EF-CC8B-4E57-BF3F-92EDD33BE822Q40723071-80186095-687C-4716-87A7-B2460A28A1B5Q40993777-F878D457-2DCD-481D-AADE-6339D333B645Q42203483-8ED4B210-0E3D-4F44-ABC1-FCF1C6608ADCQ42222507-191CC129-CABF-4990-8B06-8D1BDDCFD718Q48182798-9FC363F7-E24F-4187-9EF0-036017A9714EQ52371263-E0216B05-5B85-4C0D-87EE-7D9D1ADAACD5Q53467883-F62158BF-4D2D-4C9D-B9F7-C61E8DF35BF6Q53822207-608266E5-FF8B-42F2-9407-F27B3ABF926BQ58998353-9A74109B-4E5C-450C-8CE2-A1EAA6C32CC6
P2860
A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
A 16-year multi-institutional ...... c heart transplant recipients.
@en
A 16-year multi-institutional ...... c heart transplant recipients.
@nl
type
label
A 16-year multi-institutional ...... c heart transplant recipients.
@en
A 16-year multi-institutional ...... c heart transplant recipients.
@nl
prefLabel
A 16-year multi-institutional ...... c heart transplant recipients.
@en
A 16-year multi-institutional ...... c heart transplant recipients.
@nl
P2093
P2860
P1476
A 16-year multi-institutional ...... c heart transplant recipients.
@en
P2093
A I Dipchand
J F George
Pediatric Heart Transplant Study
R Chinnock
S A Webber
P2860
P304
P356
10.1111/J.1600-6143.2012.04197.X
P407
P577
2012-10-16T00:00:00Z